Can I Take Reishi Mushroom with Spironolactone?

The direct answer

Reishi mushroom and spironolactone do not have a documented, quantified interaction in human subjects. What exists is a set of separate, individually well-described pharmacologic properties that plausibly overlap: reishi's ganoderic acid triterpenes have shown antiplatelet effects in laboratory and animal models, and spironolactone can raise serum potassium and, at high doses, mildly affect clotting factor synthesis. For a healthy adult taking spironolactone at typical acne doses (50-150 mg/day) with normal kidney function and no anticoagulant use, adding a standard-dose reishi supplement (roughly 0.5-1 g/day of a non-concentrated extract) is unlikely to produce a clinically important effect, but this conclusion rests on mechanistic reasoning and extrapolation from separate drug and supplement literatures, not on a trial of the combination itself. Disclosure to a prescriber and baseline labs remain the appropriate next step before combining them, particularly for anyone on an anticoagulant or with reduced kidney function.

What spironolactone is, and why the acne indication matters

Spironolactone is an FDA-approved potassium-sparing diuretic and aldosterone antagonist, used since the 1960s for hypertension, edema, and heart failure. It blocks mineralocorticoid receptors in the kidney, reducing sodium retention and potassium excretion. At doses used for skin conditions, it also blocks androgen receptors, which is the basis for its widespread off-label use by dermatologists for hormonal acne and hirsutism in women. This acne use is not an FDA-approved indication; it is a well-established off-label practice supported by clinical experience and published case series, and it is treated as reasonable practice by dermatology guidance, but readers should understand the distinction between the approved diuretic/antihypertensive use and the off-label dermatologic use.

Spironolactone is converted in the body to two active metabolites, canrenone and 7-alpha-thiomethylspironolactone, both highly protein-bound. High protein binding is sometimes cited as a theoretical basis for interactions with other protein-bound compounds, but protein-binding displacement rarely translates into a clinically meaningful effect on its own, and no human data confirm this occurring with reishi triterpenes specifically.

What reishi mushroom is

Reishi (Ganoderma lucidum) is a mushroom used in traditional East Asian medicine and sold in the US as a dietary supplement, not an FDA-approved drug. Supplement products vary widely in what they actually contain: whole fruiting-body extracts, mycelium-based products, and triterpene-standardized concentrates behave differently, because most of the antiplatelet activity attributed to reishi comes from its triterpene acids (ganoderic acids), while its polysaccharide (beta-glucan) fraction is associated with immune-stimulating effects rather than bleeding risk. This distinction matters for interaction purposes: a mycelium powder low in triterpenes carries a different theoretical risk profile than a triterpene-standardized extract, even at the same milligram dose. General background on reishi's composition and traditional use is summarized in an NIH-affiliated reference chapter (NCBI Bookshelf, Ganoderma lucidum overview); readers should also check the NIH Office of Dietary Supplements fact sheet index for any future reishi-specific monograph (ODS fact sheets).

Three separate concerns, examined honestly

1. Bleeding and clotting risk

Laboratory and animal studies have reported that reishi triterpene compounds inhibit platelet aggregation and can prolong clotting-related lab values in animal models. These findings come from in-vitro platelet assays and rodent studies, not human clinical trials, and the specific papers behind these claims require verification against the primary literature before being cited as established fact. Spironolactone itself is not considered an anticoagulant, but patients taking it for heart failure are frequently co-prescribed warfarin or a direct oral anticoagulant for an unrelated reason. If a person is on spironolactone, an anticoagulant, and reishi simultaneously, three separate influences converge on the same hemostatic system, and that is the scenario where bleeding risk monitoring (INR, bruising, unusual bleeding) is genuinely warranted, not because spironolactone and reishi interact directly, but because the anticoagulant is the amplifying third variable.

2. Potassium load and hyperkalemia

Spironolactone's best-documented serious risk is hyperkalemia, which is why potassium monitoring is standard practice, particularly in heart failure patients and in anyone with reduced kidney function. Reishi mushroom is not a recognized major dietary source of potassium in standard capsule doses; whole-food or mushroom-powder preparations could contribute a modest additional amount, but this is a minor factor compared with overall diet and kidney function. The 2022 KDIGO chronic kidney disease guideline supports caution with spironolactone as estimated glomerular filtration rate (eGFR) declines, and anyone with an eGFR under 60 mL/min/1.73m² who wants to add any potassium-containing supplement should raise it with their prescriber or nephrologist before starting.

For young, otherwise healthy women taking spironolactone for acne, published dermatology literature has generally found that severe hyperkalemia is uncommon and that routine potassium monitoring in this specific low-risk population may add limited clinical value in the absence of other risk factors. Exact incidence figures from that literature should be confirmed against the primary publication rather than repeated as a precise percentage; the qualitative point, that risk is lower in healthy young women than in heart failure patients, is well supported.

3. CYP3A4 metabolism

Spironolactone is partly metabolized via CYP3A4. Some in-vitro studies have reported that ganoderic acid compounds can inhibit CYP3A4 in liver microsome assays, but at concentrations well above what standard oral supplement doses are expected to achieve in the gut or bloodstream. Regulatory guidance on in-vitro drug interaction data generally notes that inhibitory concentrations far above physiologically achievable levels are unlikely to translate into a meaningful in-vivo interaction. This makes a clinically significant CYP3A4 interaction unlikely at typical reishi doses (0.5-2 g/day of a non-concentrated preparation), though the margin narrows with concentrated, high-triterpene extracts taken at multi-gram doses. No human pharmacokinetic study has directly tested whether reishi changes spironolactone blood levels, so this remains a plausible-but-unconfirmed mechanism rather than an established interaction.

Evidence-status interaction assessment

This is a structured way to see what is actually known versus assumed, organized by the strength of evidence behind each claim.

What to actually do before combining them

Disclose the supplement. Bring the product label to your prescriber or pharmacist visit. The label should show whether the product is a fruiting-body or mycelium extract, the standardization percentage (polysaccharide and triterpene content), and the serving size in milligrams. A triterpene-standardized concentrate is a different risk profile than a whole-mushroom powder even at the same gram dose.

Get baseline labs if you don't already have recent ones. Serum potassium, a basic metabolic panel including kidney function (eGFR), and a complete blood count with platelet count are reasonable baseline checks for anyone starting spironolactone long-term; adding reishi is a reasonable prompt to confirm these are current rather than ordering new tests purely because of the supplement.

Flag anticoagulant use specifically. If you are on warfarin, a direct oral anticoagulant, or a prescription or over-the-counter antiplatelet drug (including regular aspirin), tell your prescriber before adding reishi, and expect closer monitoring, including INR checks if applicable.

Keep the dose conservative if you proceed. A whole fruiting-body reishi product at 500-1,000 mg/day carries a lower theoretical triterpene load than a concentrated extract at several grams per day. There is no clinical trial establishing a "safe" threshold for this specific combination; conservative dosing narrows the plausible risk rather than eliminating an unquantified one.

Do not stop spironolactone abruptly if you're already taking both and want to reassess. Abrupt discontinuation can cause rebound blood pressure elevation in hypertensive patients or a return of acne symptoms. Schedule a visit and let your provider review current labs before changing anything.

Pause before procedures. If you have any anticoagulant-relevant supplement on board, including reishi, tell your surgical or procedural team in advance; stopping supplements with antiplatelet potential roughly two weeks before a planned procedure is a common general precaution, though the exact timing should come from the team performing the procedure.

Who should be most cautious

• Anyone with an eGFR under 60 mL/min/1.73m², where potassium handling is already impaired
• Anyone on warfarin, a DOAC, or a regular antiplatelet medication
• Anyone using a concentrated, triterpene-standardized reishi extract at multi-gram daily doses rather than a whole-food preparation
• Anyone with an autoimmune condition or on immunosuppressive therapy, since reishi's beta-glucan fraction is immune-stimulating and the interaction with an autoimmune disease course is theoretical and unstudied
• Anyone with pre-existing liver disease, given case reports linking high-dose, prolonged reishi use to reversible liver injury independent of spironolactone

When to seek urgent care rather than wait for a routine visit

Unusual bruising, blood in urine or stool, prolonged bleeding from a minor cut, muscle weakness or heart palpitations (possible hyperkalemia symptoms), or jaundice and dark urine (possible liver injury) while taking both spironolactone and reishi warrant prompt medical evaluation rather than waiting for a scheduled follow-up.

What is established, what is plausible, and what remains unknown

Established: spironolactone causes hyperkalemia and is monitored for this reason; spironolactone's off-label acne use is a well-recognized dermatologic practice; reishi's triterpene compounds show antiplatelet activity in laboratory and animal studies. Plausible but unconfirmed in humans: a CYP3A4-mediated pharmacokinetic interaction that would raise spironolactone levels, an additive acne benefit from reishi's 5-alpha-reductase-inhibiting activity, and a clinically meaningful bleeding-risk increase in someone taking spironolactone and reishi without a separate anticoagulant. Not established: any human trial data quantifying a spironolactone-reishi interaction of any kind. Readers and clinicians should treat this combination as unstudied rather than as either cleared or contraindicated, and calibrate caution to the presence of the amplifying factors above (anticoagulant use, reduced kidney function, concentrated extract dosing).